TOP TEN perturbations for NM_000025 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000025
Selected probe(set): 206812_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000025 (206812_at) across 5392 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 14 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-1.8674688
Number of Samples:4 / 4
Experimental ovarian tumor study 14
Human pooled cancer samples from the ovary of patients with moderate and poorly differentiated serous carcinoma of the ovary.
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

TC-71 / TC-32

Relative Expression (log2-ratio):1.743371
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing?s sarcoma. Synonyms:TC32 Cellosaurus code:

ovarian tumor study 15 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-1.2611704
Number of Samples:4 / 4
Experimental ovarian tumor study 15
Human pooled cancer samples from the ovary of patients with low-malignant (borderline) serous carcinoma of the ovary.
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

Ewing sarcoma study 1 (primary; relapse) / Ewing sarcoma study 1 (primary; no relapse)

Relative Expression (log2-ratio):-1.108839
Number of Samples:17 / 12
Experimental Ewing sarcoma study 1 (primary; relapse)
Primary tumor tissue sample obtained from the bone of patients with Ewing sarcoma. Patients did have a relapse after treatment during follow-up.
Control Ewing sarcoma study 1 (primary; no relapse)
Primary tumor tissue sample obtained from the bone of patients with Ewing sarcoma. Patients did not have any evidence of disease after treatment during follow-up.

male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):1.038537
Number of Samples:2 / 8
Experimental male infertility study 1 (juvenile; Ad-)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-1.023572
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):1.0180616
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):1.0055017
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / EWS/FLI-1 depletion study 3 (NT siRNA)

Relative Expression (log2-ratio):-0.9833431
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control EWS/FLI-1 depletion study 3 (NT siRNA)
Neuroepitheliomal SK-N-MC cells transfected with 1 nM non-targeting siRNA (NT siRNA) for 24 hours. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.

plicamycin study 2 (100 nM) / vehicle (PBS) treated TC-71 cell sample

Relative Expression (log2-ratio):-0.8978329
Number of Samples:3 / 3
Experimental plicamycin study 2 (100 nM)
TC-71 Ewing?s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-71 cell sample
TC-71 Ewing?s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.